Join        Login             Stock Quote

Vivus (VVUS) Downgraded To 'Sell' By Brean Capital On Unwarranted Recent Optimism

 January 17, 2013 12:03 PM

(By Balaseshan) Vivus Inc. (NASDAQ: VVUS) shares were downgraded to "Sell" from "Hold" by Brean Capital due to unwarranted recent optimism.

Analyst Jonathan Aschoff said that as of his meeting with the biopharmaceutical company's management last week, still only 1 in 5 patients are covered by insurance for Qsymia, leading to continued prescription sticker shock even with free low dose drug as offered by Vivus ($150 versus almost twice that amount) for most patients.

Regarding the company's Get Started! program for free low dose Qsymia, management indicated that it is likely to alter it sometime after January, but it cannot get cheaper than free, and all that has been learned since launch indicates that paying more certainly will not reduce prescription abandonment, the analyst noted.

[Related -Futures Up After China Data; Citi (C), AT&T Inc. (T),Leap Wireless International Inc. (LEAP) In Focus]

In relation to the reimbursement, Aschoff does not know how many patients can actually benefit from the recent deal with Express Scripts due to the numerous payor exclusions for obesity medications.

Regarding the REMS modifications proposed by Vivus to the FDA, the analyst has yet to find a drug that had its REMS altered so soon after launch, and clearly Vivus has not sold enough drug for long enough to possibly have generated data arguing against the current REMS.

Aschoff has lowered 4Q-2012 Qsymia revenue estimate to $2 million and have cut future estimates as well. The competitive environment is only going to increase, in his view, and both Arena and Orexigen will have larger salesforces, with Orexigen having the best mix of efficacy, safety, CVOT data, and salesforce strength, and with far more minor competition from Arena, in his view.

[Related -Stocks Off Over 1 Pct After Bernanke Comments; VIVUS, Inc. (VVUS) Gains]

The brokerage, with $7 price target on the stock, widened its 2012 loss per share estimate to $1.27 from $1.23 and its 2013 loss estimate to $1.49 from $0.62.

VVUS is trading down 4.89% at $13.62 on Thursday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageGermany Is On The Rebound - Time To Buy?

Based on this year's 17% spike in the Stoxx Europe 600 Index, it seems investors have found a home in read on...

article imageIs Drought Risk In The American West An Economic Threat?

The historic and ongoing drought in California is getting harder to ignore in terms of its potential impact read on...

article imageFunds Behaving Badly

Discipline is still the key to read on...

article imageGenuine Parts Co. (GPC): This Company's Raised Dividends For 59 Years

There are 253 million cars and trucks driving along U.S. roads. And the average age of those automobiles is read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Top Insider Purchases: OPK, VVUS, LIOX, NTS, NSPR
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.